Patents by Inventor Nina Rautonen
Nina Rautonen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200376045Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: ApplicationFiled: February 10, 2020Publication date: December 3, 2020Inventors: Heli Anglenius, Kirsti Tiihonen, Nina Rautonen, Arthur Ouwehand
-
Patent number: 10555977Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: GrantFiled: April 26, 2018Date of Patent: February 11, 2020Assignee: DuPont Nutrition Biosciences ApSInventors: Heli Anglenius, Kirsti Tiihonen, Nina Rautonen, Arthur Ouwehand
-
Patent number: 10543239Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.Type: GrantFiled: December 30, 2015Date of Patent: January 28, 2020Assignee: DuPont Nutrition Biosciences ApSInventors: Remy Burcelin, Didier Carcano, Pierre Desreumaux, Sampo Lahtinen, Nina Rautonen, Heli Putaala, Kirsti Tiihonen, Rodolphe Barrangou
-
Publication number: 20190099454Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: ApplicationFiled: April 26, 2018Publication date: April 4, 2019Inventors: HELI PUTAALA, KIRSTI TIIHONEN, NINA RAUTONEN, ARTHUR OUWEHAND
-
Publication number: 20160113976Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.Type: ApplicationFiled: December 30, 2015Publication date: April 28, 2016Inventors: REMY BURCELIN, DIDIER CARCANO, PIERRE DESREUMAUX, SAMPO LAHTINEN, NINA RAUTONEN, HELI PUTAALA, KIRSTI TIIHONEN, RODOLPHE BARRANGOU
-
Patent number: 9259447Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.Type: GrantFiled: July 30, 2010Date of Patent: February 16, 2016Assignee: DUPONT NUTRITION BIOSCIENCES APSInventors: Rémy Burcelin, Didier Carcano, Pierre Desreumaux, Sampo Lahtinen, Nina Rautonen, Heli Putaala, Kirsti Tiihonen, Rodolphe Barrangou
-
Publication number: 20160008412Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: ApplicationFiled: September 22, 2015Publication date: January 14, 2016Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Heli Putaala, Arthur Ouwehand, Kirsti Tihonen, Nina Rautonen
-
Publication number: 20150224153Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms.Type: ApplicationFiled: December 17, 2014Publication date: August 13, 2015Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Erika ISOLAURI, Arthur OUWEHAND, Nina RAUTONEN, Seppo Jaakko SALMINEN
-
Patent number: 8936928Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. Suitably, such compositions may comprise L. acidophilus, B. lactis or both.Type: GrantFiled: March 26, 2008Date of Patent: January 20, 2015Assignee: Dupont Nutrition Biosciences APSInventors: Arthur Ouwehand, Nina Rautonen, Seppo Jaakko Salminen, Erika Isolauri
-
Publication number: 20140065209Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: ApplicationFiled: May 2, 2012Publication date: March 6, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Heli Putaala, Arthur Ouwehand, Kirsti Tiihonen, Nina Rautonen
-
Patent number: 8257695Abstract: Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.Type: GrantFiled: January 28, 2007Date of Patent: September 4, 2012Assignee: DuPont Nutrition Biosciences ApSInventors: Nina Rautonen, Heli Putaala, Arthur Ouwehand, Kirsti Tiihonen, Marta Korczynska, Wouter Herman Noordman
-
Publication number: 20100189692Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms.Type: ApplicationFiled: March 26, 2008Publication date: July 29, 2010Inventors: Erika Isolauri, Arthur Ouwehand, Nina Rautonen, Seppo Jaakko Salminen
-
Publication number: 20100061967Abstract: Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.Type: ApplicationFiled: January 28, 2007Publication date: March 11, 2010Inventor: Nina Rautonen
-
Publication number: 20080038228Abstract: The present invention relates to the use of a microorganism and/or a metabolite thereof to at least increase the amount of a COX-1 mRNA in a cell. The present invention further relates to the use of a microorganism and/or a metabolite thereof in the manufacture of a medicament to treat the side effects associated with nonsteroidal antiinflammatory drugs (NSAIDs). The present invention further relates to a pharmaceutical preparation comprising in combination a nonsteroidal antiinflammatory drug (NSAIDs) and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The present invention yet further relates to a pharmaceutical preparation comprising in combination betaine or a pharmaceutically acceptable salt thereof and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The microorganism may suitably be a bacterium, preferably from the genus Bifidobacterium.Type: ApplicationFiled: September 24, 2004Publication date: February 14, 2008Applicant: Danisco A/SInventors: Nina Rautonen, Jussi Nurmi, Paivi Nurminen, Pauli Puolakkainen
-
Publication number: 20060134091Abstract: The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention comprise the inclusion of a xylanase and/or an ?-amylase in the agent. A nutritional additive comprising a combination of an inner salt of a quaternary amine carboxylic acid protease and (optionally) a xylanase and an ?-amylase is also disclosed. It can be used for improving the rate of weight gain of animals.Type: ApplicationFiled: February 10, 2006Publication date: June 22, 2006Inventors: Juha Apajalahti, Nina Rautonen, Michael Bedford
-
Patent number: 7014863Abstract: The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention comprise the inclusion of a xylanase and/or an ?-amylase in the agent. A nutritional additive comprising a combination of an inner salt of a quaternary amine carboxylic acid protease and (optionally) a xylanase and an ?-amylase is also disclosed. It can be used for improving the rate of weight gain of animals.Type: GrantFiled: June 7, 2002Date of Patent: March 21, 2006Assignee: Finfeeds International LimitedInventors: Juha Apajalahti, Nina Rautonen, Michael Richard Bedford
-
Publication number: 20050288250Abstract: A process for preventing colon fermentation imbalance by the administration of a composition of a slowly fermented carbohydrate complex oligomer or polymer. A method of preparing the composition by nutritionally, nutraceutically and/or pharmacologically formulating the carbohydrate oligomer or polymer is an aspect of this process.Type: ApplicationFiled: September 16, 2003Publication date: December 29, 2005Applicant: Danisco A/SInventors: Nina Rautonen, Juha Apajalahti, Anu Kettunen, Osmo Siikanen
-
Publication number: 20030157146Abstract: The invention relates to the use of polydextrose for stimulating the immune response (IgA) in the gastrointestinal tract of a mammal. Furthermore, the invention provides a method to potentiate the immunostimulative effect of polydextrose by mixing at least one polyol with polydextrose, said polyol being effective to synergistically increase the immunoglobulin A (IgA) concentration in the gut of a mammal. On the other hand, the invention provides also compositions containing polydextrose and polyols in which the laxative effects of polyols are reduced and which are effective to reduce the amount of biogenic amines in the gut of a mammal.Type: ApplicationFiled: January 14, 2003Publication date: August 21, 2003Inventors: Nina Rautonen, Juha Apajalahti, Kirsti Tiihonen
-
Publication number: 20030059498Abstract: The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention comprise the inclusion of a xylanase and/or an &agr;-amylase in the agent. A nutritional additive comprising a combination of an inner salt of a quaternary amine carboxylic acid protease and (optionally) a xylanase and an &agr;-amylase is also disclosed. It can be used for improving the rate of weight gain of animals.Type: ApplicationFiled: June 7, 2002Publication date: March 27, 2003Applicant: Finnfeeds International LimitedInventors: Juha Apajalahti, Nina Rautonen, Michael Richard Bedford